From: TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
 | Before surgery | After surgery/before CTX | during CTX | after CTX | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 | mean | median | range | mean | median | range | mean | median | range | mean | median | range |
CA-125 [kU/L] | 1948 | 413 | 20-20880 | 325 | 84 | 15-5965 | 113 | 21 | 6-2562 | 72 | 15 | 5-1429 |
TIMP-1 [ng/mL] | 451 | 403 | 273-887 | 573 | 529 | 323-1000 | 377 | 351 | 204-616 | 371 | 333 | 209-990 |
VEGF [pg/mL] | 231 | 171 | 25-791 | 355 | 272 | 85-1133 | 176 | 139 | 11-558 | 192 | 147 | 11-960 |